{"id":1035,"count":2,"description":"<p>Apiksaban, p\u0131ht\u0131la\u015fmada g\u00f6revli fakt\u00f6r Xa enzimini engelleyen bir antikoag\u00fclan etken maddedir. P\u0131ht\u0131 olu\u015fma riskini azalt\u0131r; g\u00fcnl\u00fck dilde \u201ckan suland\u0131r\u0131c\u0131\u201d olarak an\u0131lsa da kan\u0131n b\u00fct\u00fcn \u00f6zelliklerini de\u011fi\u015ftirerek \u00e7al\u0131\u015fan bir \u00fcr\u00fcn de\u011fildir. Yarar\u0131 ile kanama riski birlikte de\u011ferlendirilir.<\/p><h2>Hangi ama\u00e7larla kullan\u0131labilir?<\/h2><p>Se\u00e7ilmi\u015f atriyal fibrilasyon hastalar\u0131nda inme riskinin azalt\u0131lmas\u0131, toplardamar p\u0131ht\u0131s\u0131 veya akci\u011fer embolisinin tedavisi ve baz\u0131 ameliyatlardan sonra p\u0131ht\u0131lar\u0131n \u00f6nlenmesi genel kullan\u0131m alanlar\u0131 aras\u0131ndad\u0131r. Bunlar ayn\u0131 tedavi plan\u0131 de\u011fildir. Kullan\u0131m amac\u0131, ya\u015f, b\u00f6brek i\u015flevi ve di\u011fer \u00f6zellikler ki\u015fiye uygunlu\u011fu etkiler. Farkl\u0131 g\u00fc\u00e7teki tabletler veya ba\u015fka antikoag\u00fclanlar aras\u0131nda ki\u015fisel doz e\u015fle\u015ftirmesi yap\u0131lmamal\u0131d\u0131r.<\/p><h2>Kanama belirtileri ve etkile\u015fimler<\/h2><p>Kolay morarma, burun veya di\u015f eti kanamas\u0131 g\u00f6r\u00fclebilir. Durmayan kanama, idrar ya da d\u0131\u015fk\u0131da kan, kanl\u0131 kusma veya kafa travmas\u0131 sa\u011fl\u0131k de\u011ferlendirmesi gerektirir. Ameliyat ve di\u015f i\u015flemi \u00f6ncesinde apiksaban kullan\u0131ld\u0131\u011f\u0131 bildirilmelidir; ilac\u0131 b\u0131rakma veya ara verme plan\u0131 ki\u015fisel kararla olu\u015fturulmamal\u0131d\u0131r. Ba\u015fka antikoag\u00fclanlar, baz\u0131 a\u011fr\u0131 kesiciler, mantar ila\u00e7lar\u0131 ve di\u011fer tedaviler birlikte kullan\u0131m a\u00e7\u0131s\u0131ndan kontrol edilir. A\u015fa\u011f\u0131daki \u00fcr\u00fcn listesi, p\u0131ht\u0131 veya inme riskini hesaplayan bir ara\u00e7 de\u011fildir. Ayn\u0131 etken maddeyi payla\u015fan \u00fcr\u00fcnlerde bile g\u00fc\u00e7 ve ki\u015fiye uygun plan ayr\u0131 de\u011ferlendirilir. Tedavideki de\u011fi\u015fiklikler doktor veya eczac\u0131yla netle\u015ftirilmelidir.<\/p><h2>Kaynaklar ve kapsam<\/h2><ul><li><a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/eliquis\" target=\"_blank\" rel=\"noopener\">EMA: Eliquis de\u011ferlendirmesi<\/a> (Avrupa Birli\u011fi) \u2014 Fakt\u00f6r Xa mekanizmas\u0131 ve kullan\u0131m \u00e7er\u00e7evesi.<\/li><li><a href=\"https:\/\/www.nhs.uk\/medicines\/apixaban\/\" target=\"_blank\" rel=\"noopener\">NHS: Apiksaban<\/a> (Birle\u015fik Krall\u0131k) \u2014 Kanama, prosed\u00fcrler ve birlikte kullan\u0131m g\u00fcvenli\u011fi.<\/li><\/ul><p><small>Kaynak kontrol\u00fc: <time datetime=\"2026-10-11\">11 Ekim 2026<\/time>. Kaynak do\u011frulamas\u0131 klinik uzman incelemesi de\u011fildir. \u0130\u00e7erik, kaynaklara dayal\u0131 yapay zek\u00e2 destekli genel bilgi \u00f6zetidir.<\/small><\/p>","link":"https:\/\/www.ortaakarsu.net\/?ism_etken_madde=apiksaban","name":"Apiksaban","slug":"apiksaban","taxonomy":"ism_etken_madde","meta":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/ism_etken_madde\/1035","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/ism_etken_madde"}],"about":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/taxonomies\/ism_etken_madde"}],"wp:post_type":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fism_drug&ism_etken_madde=1035"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}